SCHEMBL14263115

SCHEMBL14263115

CCCCCCCCC(=O)OC(C)CN(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
MAPT P10636 3/20 0.54
MAPK1 P28482 3/20 0.54
DNM1 Q05193 1/20 0.51
ALDH1A1 P00352 1/20 0.51
PRKCA P17252 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCQ Q04759 1/20 0.47
PRKCD Q05655 1/20 0.47
DGKA P23743 1/20 0.47
TSHR P16473 2/20 0.47
CYP1A2 P05177 2/20 0.44
MEN1 O00255 1/20 0.44
GMNN O75496 1/20 0.44
HSP90AA1 P07900 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8396305 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394182 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL872500 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL465982 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394932 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL15228719 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394166 0.98 LMNA (0.59) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL992184 0.91 PRKCA (0.54) LMNAMAPTALDH1A1PRKCAPRKCE
SCHEMBL465985 0.91 PRKCA (0.54) LMNAMAPTALDH1A1PRKCAPRKCE
SCHEMBL31374704 0.87 ALDH1A1 (0.58) LMNAMAPTALDH1A1PRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11246932-B2 Prostaglandin compositions and methods for the treatment of vasospasm NEXMED HOLDINGS, INC. (US) 2022-02-15 US disclosed
US-20190076529-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM NEXMED HOLDINGS, INC. (US) 2019-03-14 US disclosed
US-20150272875-A1 ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION NEXMED HOLDINGS, INC. (US) 2015-10-01 US disclosed
US-9066854-B2 Alprostadil and dyclonine for treatment of premature ejaculation NEXMED HOLDINGS, INC. (US) 2015-06-30 US disclosed
US-9060929-B2 Alprostadil for treatment of premature ejaculation NEXMED HOLDINGS, INC. (US) 2015-06-23 US disclosed
US-9056044-B2 Alprostadil and lidocaine treatment of premature ejaculation NEXMED HOLDINGS, INC. (US) 2015-06-16 US disclosed
US-20150011587-A1 ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION NEXMED HOLDINGS, INC. (US) 2015-01-08 US disclosed
US-20150011638-A1 ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION NEXMED HOLDINGS, INC. (US) 2015-01-08 US disclosed
US-20150011585-A1 ALPROSTADIL AND DYCLONINE FOR TREATMENT OF PREMATURE EJACULATION NEXMED HOLDINGS, INC. (US) 2015-01-08 US disclosed
US-8841345-B2 Compositions and methods for treatment of premature ejaculation NEXMED HOLDINGS, INC. (US) 2014-09-23 US disclosed
US-20140206766-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM NEXMED HOLDINGS, INC. (US) 2014-07-24 US disclosed
US-20140142188-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM NEXMED HOLDINGS, INC. (US) 2014-05-22 US disclosed
US-8632813-B2 Prostaglandin compositions and methods for the treatment of vasospasm NEXMED (HOLDINGS), INC. (US) 2014-01-21 US disclosed
US-20080069883-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM NEXMED HOLDINGS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011638-A1 ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION LPXN, LMNB1, PLA2G10 LMNA 5/4885MAPT 1713/4885MAPK1 2568/4885
US-20190076529-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM PTGIS, PTGIR, PGF LMNA 2078/4885MAPT 3730/4885MAPK1 4752/4885
US-20140142188-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM PTGIS, PTGIR, PGF LMNA 2078/4885MAPT 3730/4885MAPK1 4752/4885
US-20150011587-A1 ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION PTGER1, PLA2G10, PDE12 LMNA 42/4885MAPT 1502/4885MAPK1 2871/4885
US-20140206766-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM PTGIS, PTGIR, PGF LMNA 2078/4885MAPT 3730/4885MAPK1 4752/4885
US-11246932-B2 Prostaglandin compositions and methods for the treatment of vasospasm PTGIS, PTGIR, PGF LMNA 2078/4885MAPT 3730/4885MAPK1 4752/4885
US-20080069883-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM PTGIS, PTGIR, PGF LMNA 2078/4885MAPT 3730/4885MAPK1 4752/4885
US-20150011585-A1 ALPROSTADIL AND DYCLONINE FOR TREATMENT OF PREMATURE EJACULATION DAGLA, PHOSPHO1, PLD1 LMNA 143/4885MAPT 414/4885MAPK1 1470/4885
US-20150272875-A1 ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION PTGER1, PLA2G10, PDE12 LMNA 42/4885MAPT 1502/4885MAPK1 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.